Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by DKBmed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DKBmed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Emerging MS Clinical Options

24:18
 
Share
 

Manage episode 385239857 series 2065653
Content provided by DKBmed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DKBmed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?


Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)


Hosted on Acast. See acast.com/privacy for more information.

  continue reading

220 episodes

Artwork

Emerging MS Clinical Options

DKBmed Radio

14 subscribers

published

iconShare
 
Manage episode 385239857 series 2065653
Content provided by DKBmed. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by DKBmed or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Has the place for BTK inhibitors in MS been determined? How well do extended interval or alternative B cell depletion dosing regimens work, and for which patients? Do the data support HSCT (hematopoietic stem cell transplant) over high-efficacy DMT — again, for which patients, and with what efficacy and safety?


Join us, as guest host Dr. Cole Harrington from the Ohio State University explores these important topics in this issue of eMultipleSclerosis Review.


Take our post-test to claim CME credits (https://elit.dkbmed.com/issues/178/test)

Read this podcast's companion newsletter here. (https://elit.dkbmed.com/issues/176)


Hosted on Acast. See acast.com/privacy for more information.

  continue reading

220 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play